Agilent Announces Cash Dividend of 24.8 Cents per Share

$A
Biotechnology: Laboratory Analytical Instruments
Industrials
Get the next $A alert in real time by email

Agilent Technologies, Inc. (NYSE:A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on April 23, 2025, to all shareholders of record as of the close of business on April 1, 2025.

The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors.

About Agilent Technologies

Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Forward-Looking Statements

This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding the company's dividend program and future payment obligations. These forward-looking statements involve risks and uncertainties that could cause Agilent's results to differ materially from management's current expectations. Such risks and uncertainties are detailed in Agilent's filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the fiscal year ended Oct. 31, 2024. Forward-looking statements are based on the beliefs and assumptions of Agilent's management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.

INVESTOR CONTACT:

Parmeet Ahuja

+1 408-345-8948

Parmeet_Ahuja@agilent.com

MEDIA CONTACT:

Andréa Topper

+1 408-709-0060

andrea.topper@agilent.com

Get the next $A alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$A

DatePrice TargetRatingAnalyst
2/10/2025$135.00 → $145.00Underweight → Equal Weight
Barclays
8/28/2024$157.00Overweight
Wells Fargo
7/10/2024$135.00 → $150.00Neutral → Buy
Citigroup
6/27/2024Outperform → Peer Perform
Wolfe Research
6/3/2024$135.00Hold
Jefferies
4/5/2024$145.00 → $163.00Hold → Buy
Stifel
12/13/2023$140.00Outperform
Wolfe Research
12/12/2023$130.00 → $133.00Buy → Neutral
BofA Securities
More analyst ratings

$A
Press Releases

Fastest customizable press release news feed in the world

See more
  • Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval

    Innovative technology supports testing of accuracy and reliability in Autolus Therapeutics' recently approved CAR T therapy AUCATZYL® Agilent Technologies Inc. (NYSE:A) is pleased to announce its role in supporting Autolus Therapeutics' FDA approval for AUCATZYL®, a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the xCELLigence Real-Time Cell Analysis (RTCA) technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required f

    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Agilent to Showcase Next-Generation Digital Pathology Solutions at USCAP 2025

    Agilent Technologies Inc. (NYSE:A) is excited to announce its participation at the upcoming United States and Canadian Academy of Pathology (USCAP) Conference, which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzing tissue samples, often for diagnosing diseases such as cancer. In collaboration with Hamamatsu, PathAI, Proscia, and Visiopharm, Agilent has developed an innovative end-to-end digital pathology workflow. This solution integrates AI-driven precision pathology software

    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Agilent Research Catalyst Award Presented to Columbia University for Professor Pawel Muranski

    Scientist recognized for pioneering advances in bioprocess development and biomanufacturing Agilent Technologies Inc. (NYSE:A) today announced that Columbia University has received an Agilent Research Catalyst (ARC) Award on behalf of Dr. Pawel Muranski, an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of

    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$A
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$A
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$A
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$A
SEC Filings

See more

$A
Leadership Updates

Live Leadership Updates

See more
  • Agilent to Acquire North American CDMO BIOVECTRA

    Expands Agilent's end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing Agilent Technologies Inc. (NYSE:A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722078870/en/A BIOVECTRA manufacturing facility (Photo: Business Wire) Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. The acquisition builds on Agilent's CDMO specializati

    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

    Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

    $A
    $ANIK
    $AVNT
    $MASI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical/Dental Instruments
    Health Care
  • Agilent Unveils the 8850 Gas Chromatograph: A Leap Forward in Analytical Excellence

    New instrument delivers the full power and capability of Agilent GCs in a compact design SANTA CLARA, Calif., May 23, 2024 /PRNewswire/ -- Agilent Technologies Inc. (NYSE:A) proudly announces the 8850 Gas Chromatograph (GC) System, a small single-channel GC that combines the legacy of the 6850 GC with the capability and system intelligence of the 8890 GC. With a focus on speed and intelligence, the 8850 GC stands poised to revolutionize labs across diverse markets, including energy, chemicals, food, and pharmaceuticals while reducing energy consumption up to 30%. Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9270251-agilent-unveils-8

    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$A
Financials

Live finance-specific insights

See more
  • Agilent Reports First-Quarter Fiscal Year 2025 Financial Results

    Delivers solid Q1 results, confirms core growth and EPS for 2025 fiscal year First-quarter fiscal year 2025 Revenue of $1.68 billion for the first quarter ended Jan. 31, 2025, representing growth of 1.4% reported and up 1.2% on a core(1) basis compared with the first quarter of 2024. GAAP net income of $318 million; earnings per share (EPS) of $1.11, down 6% from the first quarter of 2024. Non-GAAP(2) net income of $377 million; EPS of $1.31, up 2% from the first quarter of 2024. Outlook for full 2025 fiscal year and Q2 Full-year revenue outlook is now in the range of $6.68 billion to $6.76 billion, representing a range of up 2.6% to 3.8% reported and 2.5% to 3.5% core(1).

    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Agilent Announces Cash Dividend of 24.8 Cents per Share

    Agilent Technologies, Inc. (NYSE:A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on April 23, 2025, to all shareholders of record as of the close of business on April 1, 2025. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted a

    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Agilent to Announce First-Quarter Fiscal Year 2025 Financial Results on Feb. 26

    Agilent Technologies Inc. (NYSE:A) will release financial results for the first quarter of fiscal year 2025 after the stock market closes on Wednesday, Feb. 26. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PST. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full

    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$A
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more